Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tildacerfont · SPR-001, LY-2371712

Small molecule · Antagonist of corticotropin-releasing factor type 1 receptor (CRHR1) · developed by Spruce Biosciences

Phase 2 Most advanced trial (none active)
SPRB Developer
2 Registered trials

What is Tildacerfont?

Tildacerfont is an orally bioavailable, selective nonsteroidal antagonist of the corticotropin-releasing factor type 1 (CRF1) receptor in the pituitary gland. By blocking this receptor it reduces ACTH secretion and the overproduction of adrenal androgens. It is studied in congenital adrenal hyperplasia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SPR-001, LY-2371712
Drug type
Small molecule
Targets
corticotropin-releasing factor type 1 receptor (CRHR1)
Mechanism
Antagonist of corticotropin-releasing factor type 1 receptor (CRHR1)
Pathways
hypothalamic-pituitary-adrenal axis, ACTH secretion, adrenal androgen production
Therapy area
Endocrine
Developer
Spruce Biosciences (SPRB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
09QCEV5481

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05128942 Phase 2 Congenital Adrenal Hyperplasia Terminated SPRB
NCT03257462 Phase 2 Congenital Adrenal Hyperplasia Completed SPRB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

21-OHDCAH - Congenital Adrenal HyperplasiaCongenital Adrenal Hyperplasia

Other drugs acting on CRHR1

More from Spruce Biosciences

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SPRB page.

Follow SPRB, the company behind Tildacerfont

See SPRB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SPRB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.